Chemical Nameselinexor
Dosage FormTablet (oral; 20 mg)
Drug ClassInhibitors
CompanyKaryopharm Therapeutics
Approval Year2019


  • Xpovio is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Last updated on 10/29/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xpovio (selinexor) Prescribing Information 2019Karyopharm Therapeutics